Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) EBIT per Share : $0.63 (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals EBIT per Share?

Clinuvel Pharmaceuticals's EBIT per Share for the six months ended in Dec. 2023 was $0.22. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.63.

During the past 12 months, the average EBIT per Share Growth Rate of Clinuvel Pharmaceuticals was 2.90% per year. During the past 3 years, the average EBIT per Share Growth Rate was 55.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 30.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Clinuvel Pharmaceuticals's EBIT per Share or its related term are showing as below:

CLVLF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -40.7 Med: 15.9 Max: 55.6
Current: 55.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Clinuvel Pharmaceuticals was 55.60% per year. The lowest was -40.70% per year. And the median was 15.90% per year.

CLVLF's 3-Year EBIT Growth Rate is ranked better than
94.58% of 1311 companies
in the Biotechnology industry
Industry Median: 3.6 vs CLVLF: 55.60

Clinuvel Pharmaceuticals's EBIT for the six months ended in Dec. 2023 was $11.26 Mil.

Clinuvel Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Clinuvel Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals EBIT per Share Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT per Share

Get a 7-Day Free Trial

0.25

0.18

0.41

0.50

0.63

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.13	0.36	0.22	0.41	0.22

Clinuvel Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Clinuvel Pharmaceuticals's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	32.732	/	51.784
=	0.63

Clinuvel Pharmaceuticals's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	11.262	/	51.585
=	0.22

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.63

Clinuvel Pharmaceuticals (OTCPK:CLVLF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Clinuvel Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.